Implant Site Nexplanon Reaction?

Detalhes bibliográficos
Autor(a) principal: Pedroso, C
Data de Publicação: 2015
Outros Autores: Martins, I, Palma, F, Machado, AI
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
Texto Completo: http://hdl.handle.net/10400.17/2407
Resumo: Nexplanon (Schering-Plough Limited/Merck Sharp & Dohme Limited (MSD)) is a long active reversible contraceptive method that provides effective contraception for 3 years. It consists of a single, flexible, rod-shaped implant, containing 68 mg etonogestrel. It is 4 cm long, consists of an ethylene vinyl acetate copolymer, a non-absorbable material, and also contains 15 mg of barium sulfate, which makes it visible by X-ray. We describe a case of a 39-year-old woman who experienced a local reaction to the barium sulfate in Nexplanon. She was given medical treatment, but only the removal of the implant resolved the symptoms. After removal there was gradual improvement and 72 h later the patient was asymptomatic. Allergic reaction to barium sulfate is extremely rare: until now, there have only been two cases associated with Nexplanon described in the literature.
id RCAP_cef4392ac3d68edf917a05fe680129f7
oai_identifier_str oai:repositorio.chlc.min-saude.pt:10400.17/2407
network_acronym_str RCAP
network_name_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository_id_str 7160
spelling Implant Site Nexplanon Reaction?MAC GINMAC OBSBarium Sulfate/adverse effectsContraceptive Agents, Female/administration & dosageContraceptive Agents, Female/adverse effectsDesogestrel/adverse effectsDevice RemovalDrug Eruptions/etiologyDrug Implants/adverse effectsTreatment OutcomeNexplanon (Schering-Plough Limited/Merck Sharp & Dohme Limited (MSD)) is a long active reversible contraceptive method that provides effective contraception for 3 years. It consists of a single, flexible, rod-shaped implant, containing 68 mg etonogestrel. It is 4 cm long, consists of an ethylene vinyl acetate copolymer, a non-absorbable material, and also contains 15 mg of barium sulfate, which makes it visible by X-ray. We describe a case of a 39-year-old woman who experienced a local reaction to the barium sulfate in Nexplanon. She was given medical treatment, but only the removal of the implant resolved the symptoms. After removal there was gradual improvement and 72 h later the patient was asymptomatic. Allergic reaction to barium sulfate is extremely rare: until now, there have only been two cases associated with Nexplanon described in the literature.BMJ Publishing GroupRepositório do Centro Hospitalar Universitário de Lisboa Central, EPEPedroso, CMartins, IPalma, FMachado, AI2016-03-04T16:26:47Z20152015-01-01T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttp://hdl.handle.net/10400.17/2407engBMJ Case Rep. 2015 May 7;201510.1136/bcr-2014-206256info:eu-repo/semantics/openAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2023-03-10T09:36:50Zoai:repositorio.chlc.min-saude.pt:10400.17/2407Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-19T17:19:45.722105Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse
dc.title.none.fl_str_mv Implant Site Nexplanon Reaction?
title Implant Site Nexplanon Reaction?
spellingShingle Implant Site Nexplanon Reaction?
Pedroso, C
MAC GIN
MAC OBS
Barium Sulfate/adverse effects
Contraceptive Agents, Female/administration & dosage
Contraceptive Agents, Female/adverse effects
Desogestrel/adverse effects
Device Removal
Drug Eruptions/etiology
Drug Implants/adverse effects
Treatment Outcome
title_short Implant Site Nexplanon Reaction?
title_full Implant Site Nexplanon Reaction?
title_fullStr Implant Site Nexplanon Reaction?
title_full_unstemmed Implant Site Nexplanon Reaction?
title_sort Implant Site Nexplanon Reaction?
author Pedroso, C
author_facet Pedroso, C
Martins, I
Palma, F
Machado, AI
author_role author
author2 Martins, I
Palma, F
Machado, AI
author2_role author
author
author
dc.contributor.none.fl_str_mv Repositório do Centro Hospitalar Universitário de Lisboa Central, EPE
dc.contributor.author.fl_str_mv Pedroso, C
Martins, I
Palma, F
Machado, AI
dc.subject.por.fl_str_mv MAC GIN
MAC OBS
Barium Sulfate/adverse effects
Contraceptive Agents, Female/administration & dosage
Contraceptive Agents, Female/adverse effects
Desogestrel/adverse effects
Device Removal
Drug Eruptions/etiology
Drug Implants/adverse effects
Treatment Outcome
topic MAC GIN
MAC OBS
Barium Sulfate/adverse effects
Contraceptive Agents, Female/administration & dosage
Contraceptive Agents, Female/adverse effects
Desogestrel/adverse effects
Device Removal
Drug Eruptions/etiology
Drug Implants/adverse effects
Treatment Outcome
description Nexplanon (Schering-Plough Limited/Merck Sharp & Dohme Limited (MSD)) is a long active reversible contraceptive method that provides effective contraception for 3 years. It consists of a single, flexible, rod-shaped implant, containing 68 mg etonogestrel. It is 4 cm long, consists of an ethylene vinyl acetate copolymer, a non-absorbable material, and also contains 15 mg of barium sulfate, which makes it visible by X-ray. We describe a case of a 39-year-old woman who experienced a local reaction to the barium sulfate in Nexplanon. She was given medical treatment, but only the removal of the implant resolved the symptoms. After removal there was gradual improvement and 72 h later the patient was asymptomatic. Allergic reaction to barium sulfate is extremely rare: until now, there have only been two cases associated with Nexplanon described in the literature.
publishDate 2015
dc.date.none.fl_str_mv 2015
2015-01-01T00:00:00Z
2016-03-04T16:26:47Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://hdl.handle.net/10400.17/2407
url http://hdl.handle.net/10400.17/2407
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv BMJ Case Rep. 2015 May 7;2015
10.1136/bcr-2014-206256
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv BMJ Publishing Group
publisher.none.fl_str_mv BMJ Publishing Group
dc.source.none.fl_str_mv reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron:RCAAP
instname_str Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron_str RCAAP
institution RCAAP
reponame_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
collection Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository.name.fl_str_mv Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
repository.mail.fl_str_mv
_version_ 1817552109365624832

Registros relacionados